Sign in
NMRA Stock Price, Chart, Stats & News
Neumora Therapeutics, Inc. Common Stock
Save
Neumora Therapeutics, Inc. Common Stock (NMRA) does not currently pay a dividend.
311.28M
Market cap
–
Current P/E
–
Forward P/E
NMRA chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | -0.06% |
ROA | -132.88% |
ROE | -113.81% |
D/E | 0.00x |
Interest coverage ratio | -328.78x |
NMRA valuation
P/E | – |
P/S | – |
P/B | 2.85x |
P/CF | -1.81x |
P/FCF | -1.86x |
P/OCF | -1.81x |
PEG | -0.25x |
EV multiple | -2.13x |
About
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia.
Similar securities
Based on sector and market capitalization
Report issue